Drug
Jnj 1761981
Jnj 1761981: highest development phase Phase 1, developed by Johnson & Johnson. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Johnson & Johnson
Trials
| Drug | Phase | Indication |
|---|---|---|
| JNJ-1761981 NCT07525141 | Phase 1 | Neoplasms |
Latest
No recent events.
Follow Jnj 1761981 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.